Dual Pro-Angiogenic and Pro-Fibrotic MARCO+ Microglial Phenotype in Diabetic Retinopathy

  • FASEB J. 2025 Sep 15;39(17):e71006. doi: 10.1096/fj.202502138R.
Qinyuan Gu  1 Xiying Mao  1 Jingyi Xu  1 Pengfei Ge  1 Xinjing Wu  1 Chengkun Wang  2 Jingfan Wang  1 Hongying Li  1 Yuanyuan Fan  1 Tianhao Xiao  1 Qinghuai Liu  1 Ping Xie  1 Zizhong Hu  1
Affiliations
  • 1. Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • 2. Department of Physiology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Abstract

Proliferative diabetic retinopathy (PDR) is a complication of diabetic microangiopathy that can cause severe visual impairment. Due to retinal neovascularization and fibrovascular membrane (FVM) formation, inhibition of vascularization and fibrosis plays a key role in PDR. In our study, single-cell Sequencing of FVMs from PDR patients identified a MARCO+ microglial subpopulation exhibiting both pro-angiogenic and pro-fibrotic effects. In vitro experiments demonstrated that glycated albumin (GA) significantly upregulated MARCO expression in BV2 cells in a dose-dependent manner. In vivo experiments, oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV) models were established in wild-type (WT) and MARCO-/- mice. The accumulation of MARCO+ microglia promoted retinal angiogenesis and fibrogenesis in WT mouse models, but not in MARCO-/- mouse models. Mechanistically, next-generation Sequencing confirmed that the activation of the TLR4/NF-κB signaling pathway results in the increased expression of MARCO+ microglia. Furthermore, the targeted drug PolyG, which inhibits MARCO+ microglia, resulted in reduced angiogenesis and fibrogenesis in mouse models. Taken together, we demonstrate that MARCO+ microglia could be a potential therapeutic target for ocular angiogenic and fibrotic diseases.

Keywords
MARCO protein; diabetic retinopathy; fibrosis; microglia; neovascularization.
Products